XML 68 R51.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Apr. 01, 2018 | Apr. 02, 2017
Sales by segment of business |  |
Sales | $ 20,009 | $ 17,766
Percent Change (as a percent) | 12.60% |
U.S. |  |
Sales by segment of business |  |
Sales | $ 9,951 | 9,378
Percent Change (as a percent) | 6.10% |
International |  |
Sales by segment of business |  |
Sales | $ 10,058 | 8,388
Percent Change (as a percent) | 19.90% |
CONSUMER |  |
Sales by segment of business |  |
Sales | $ 3,398 | 3,228
Percent Change (as a percent) | 5.30% |
CONSUMER | U.S. |  |
Sales by segment of business |  |
Sales | $ 1,436 | 1,414
Percent Change (as a percent) | 1.60% |
CONSUMER | International |  |
Sales by segment of business |  |
Sales | $ 1,962 | 1,814
Percent Change (as a percent) | 8.20% |
CONSUMER | Baby Care |  |
Sales by segment of business |  |
Sales | $ 457 | 455
Percent Change (as a percent) | 0.40% |
CONSUMER | Baby Care | U.S. |  |
Sales by segment of business |  |
Sales | $ 97 | 113
Percent Change (as a percent) | (14.20%) |
CONSUMER | Baby Care | International |  |
Sales by segment of business |  |
Sales | $ 360 | 342
Percent Change (as a percent) | 5.30% |
CONSUMER | Beauty |  |
Sales by segment of business |  |
Sales | $ 1,084 | 981
Percent Change (as a percent) | 10.50% |
CONSUMER | Beauty | U.S. |  |
Sales by segment of business |  |
Sales | $ 611 | 567
Percent Change (as a percent) | 7.80% |
CONSUMER | Beauty | International |  |
Sales by segment of business |  |
Sales | $ 473 | 414
Percent Change (as a percent) | 14.30% |
CONSUMER | Oral Care |  |
Sales by segment of business |  |
Sales | $ 379 | 362
Percent Change (as a percent) | 4.70% |
CONSUMER | Oral Care | U.S. |  |
Sales by segment of business |  |
Sales | $ 157 | 156
Percent Change (as a percent) | 0.60% |
CONSUMER | Oral Care | International |  |
Sales by segment of business |  |
Sales | $ 222 | 206
Percent Change (as a percent) | 7.80% |
CONSUMER | OTC |  |
Sales by segment of business |  |
Sales | $ 1,072 | 1,013
Percent Change (as a percent) | 5.80% |
CONSUMER | OTC | U.S. |  |
Sales by segment of business |  |
Sales | $ 465 | 477
Percent Change (as a percent) | (2.50%) |
CONSUMER | OTC | International |  |
Sales by segment of business |  |
Sales | $ 607 | 536
Percent Change (as a percent) | 13.20% |
CONSUMER | Women's Health |  |
Sales by segment of business |  |
Sales | $ 243 | 242
Percent Change (as a percent) | 0.40% |
CONSUMER | Women's Health | U.S. |  |
Sales by segment of business |  |
Sales | $ 3 | 3
Percent Change (as a percent) | 0.00% |
CONSUMER | Women's Health | International |  |
Sales by segment of business |  |
Sales | $ 240 | 239
Percent Change (as a percent) | 0.40% |
CONSUMER | Wound Care/Other |  |
Sales by segment of business |  |
Sales | $ 163 | 175
Percent Change (as a percent) | (6.90%) |
CONSUMER | Wound Care/Other | U.S. |  |
Sales by segment of business |  |
Sales | $ 103 | 98
Percent Change (as a percent) | 5.10% |
CONSUMER | Wound Care/Other | International |  |
Sales by segment of business |  |
Sales | $ 60 | 77
Percent Change (as a percent) | (22.10%) |
PHARMACEUTICAL |  |
Sales by segment of business |  |
Sales | $ 9,844 | 8,245
Percent Change (as a percent) | 19.40% |
PHARMACEUTICAL | U.S. |  |
Sales by segment of business |  |
Sales | $ 5,354 | 4,872
Percent Change (as a percent) | 9.90% |
PHARMACEUTICAL | International |  |
Sales by segment of business |  |
Sales | $ 4,490 | 3,373
Percent Change (as a percent) | 33.10% |
PHARMACEUTICAL | Immunology |  |
Sales by segment of business |  |
Sales | $ 3,042 | 2,930
Percent Change (as a percent) | 3.80% |
PHARMACEUTICAL | Immunology | U.S. |  |
Sales by segment of business |  |
Sales | $ 2,000 | 2,123
Percent Change (as a percent) | (5.80%) |
PHARMACEUTICAL | Immunology | International |  |
Sales by segment of business |  |
Sales | $ 1,042 | 807
Percent Change (as a percent) | 29.10% |
PHARMACEUTICAL | Immunology | REMICADE® |  |
Sales by segment of business |  |
Sales | $ 1,389 | 1,672
Percent Change (as a percent) | (16.90%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |
Sales by segment of business |  |
Sales | $ 916 | 1,182
Percent Change (as a percent) | (22.50%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |
Sales by segment of business |  |
Sales | $ 142 | 165
Percent Change (as a percent) | (13.90%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |
Sales by segment of business |  |
Sales | $ 331 | 325
Percent Change (as a percent) | 1.80% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |
Sales by segment of business |  |
Sales | $ 518 | 428
Percent Change (as a percent) | 21.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 224 | 229
Percent Change (as a percent) | (2.20%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |
Sales by segment of business |  |
Sales | $ 294 | 199
Percent Change (as a percent) | 47.70% |
PHARMACEUTICAL | Immunology | STELARA® |  |
Sales by segment of business |  |
Sales | $ 1,061 | 823
Percent Change (as a percent) | 28.90% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 652 | 547
Percent Change (as a percent) | 19.20% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |
Sales by segment of business |  |
Sales | $ 409 | 276
Percent Change (as a percent) | 48.20% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales | $ 74 | 7
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales | 66 | 0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales | $ 8 | 7
Percent Change (as a percent) | 14.30% |
PHARMACEUTICAL | Infectious Diseases |  |
Sales by segment of business |  |
Sales | $ 830 | 749
Percent Change (as a percent) | 10.80% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales | $ 333 | 326
Percent Change (as a percent) | 2.10% |
PHARMACEUTICAL | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales | $ 497 | 423
Percent Change (as a percent) | 17.50% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |
Sales by segment of business |  |
Sales | $ 210 | 149
Percent Change (as a percent) | 40.90% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales | $ 14 | 12
Percent Change (as a percent) | 16.70% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |
Sales by segment of business |  |
Sales | $ 196 | 137
Percent Change (as a percent) | 43.10% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |
Sales by segment of business |  |
Sales | $ 478 | 430
Percent Change (as a percent) | 11.20% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 273 | 259
Percent Change (as a percent) | 5.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |
Sales by segment of business |  |
Sales | $ 205 | 171
Percent Change (as a percent) | 19.90% |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |
Sales by segment of business |  |
Sales | $ 142 | 170
Percent Change (as a percent) | (16.50%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |
Sales by segment of business |  |
Sales | $ 46 | 55
Percent Change (as a percent) | (16.40%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |
Sales by segment of business |  |
Sales | $ 96 | 115
Percent Change (as a percent) | (16.50%) |
PHARMACEUTICAL | Neuroscience |  |
Sales by segment of business |  |
Sales | $ 1,559 | 1,497
Percent Change (as a percent) | 4.10% |
PHARMACEUTICAL | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales | $ 624 | 664
Percent Change (as a percent) | (6.00%) |
PHARMACEUTICAL | Neuroscience | International |  |
Sales by segment of business |  |
Sales | $ 935 | 833
Percent Change (as a percent) | 12.20% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate |  |
Sales by segment of business |  |
Sales | $ 173 | 209
Percent Change (as a percent) | (17.20%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales | $ 66 | 108
Percent Change (as a percent) | (38.90%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | International |  |
Sales by segment of business |  |
Sales | $ 107 | 101
Percent Change (as a percent) | 5.90% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® |  |
Sales by segment of business |  |
Sales | $ 696 | 604
Percent Change (as a percent) | 15.20% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 400 | 372
Percent Change (as a percent) | 7.50% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | International |  |
Sales by segment of business |  |
Sales | $ 296 | 232
Percent Change (as a percent) | 27.60% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |
Sales by segment of business |  |
Sales | $ 196 | 207
Percent Change (as a percent) | (5.30%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 82 | 95
Percent Change (as a percent) | (13.70%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |
Sales by segment of business |  |
Sales | $ 114 | 112
Percent Change (as a percent) | 1.80% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales | $ 494 | 477
Percent Change (as a percent) | 3.60% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales | $ 76 | 89
Percent Change (as a percent) | (14.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales | $ 418 | 388
Percent Change (as a percent) | 7.70% |
PHARMACEUTICAL | Oncology |  |
Sales by segment of business |  |
Sales | $ 2,311 | 1,594
Percent Change (as a percent) | 45.00% |
PHARMACEUTICAL | Oncology | U.S. |  |
Sales by segment of business |  |
Sales | $ 933 | 664
Percent Change (as a percent) | 40.50% |
PHARMACEUTICAL | Oncology | International |  |
Sales by segment of business |  |
Sales | $ 1,378 | 930
Percent Change (as a percent) | 48.20% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |
Sales by segment of business |  |
Sales | $ 432 | 255
Percent Change (as a percent) | 69.40% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |
Sales by segment of business |  |
Sales | $ 264 | 201
Percent Change (as a percent) | 31.30% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |
Sales by segment of business |  |
Sales | $ 168 | 54
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |
Sales by segment of business |  |
Sales | $ 587 | 409
Percent Change (as a percent) | 43.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 227 | 190
Percent Change (as a percent) | 19.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |
Sales by segment of business |  |
Sales | $ 360 | 219
Percent Change (as a percent) | 64.40% |
PHARMACEUTICAL | Oncology | VELCADE® |  |
Sales by segment of business |  |
Sales | $ 313 | 280
Percent Change (as a percent) | 11.80% |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |
Sales by segment of business |  |
Sales | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |
Sales by segment of business |  |
Sales | $ 313 | 280
Percent Change (as a percent) | 11.80% |
PHARMACEUTICAL | Oncology | ZYTIGA® |  |
Sales by segment of business |  |
Sales | $ 845 | 523
Percent Change (as a percent) | 61.60% |
PHARMACEUTICAL | Oncology | ZYTIGA® | U.S. |  |
Sales by segment of business |  |
Sales | $ 407 | 233
Percent Change (as a percent) | 74.70% |
PHARMACEUTICAL | Oncology | ZYTIGA® | International |  |
Sales by segment of business |  |
Sales | $ 438 | 290
Percent Change (as a percent) | 51.00% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |
Sales by segment of business |  |
Sales | $ 134 | 127
Percent Change (as a percent) | 5.50% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |
Sales by segment of business |  |
Sales | $ 35 | 40
Percent Change (as a percent) | (12.50%) |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |
Sales by segment of business |  |
Sales | $ 99 | 87
Percent Change (as a percent) | 13.80% |
PHARMACEUTICAL | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales | $ 585 | 0
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales | 361 | 0
PHARMACEUTICAL | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales | 224 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |
Sales by segment of business |  |
Sales | 271 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |
Sales by segment of business |  |
Sales | 149 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |
Sales by segment of business |  |
Sales | 122 | 0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® |  |
Sales by segment of business |  |
Sales | 140 | 0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S. |  |
Sales by segment of business |  |
Sales | 68 | 0
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International |  |
Sales by segment of business |  |
Sales | 72 | 0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |
Sales by segment of business |  |
Sales | 140 | 0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |
Sales by segment of business |  |
Sales | 124 | 0
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |
Sales by segment of business |  |
Sales | 16 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |
Sales by segment of business |  |
Sales | 34 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |
Sales by segment of business |  |
Sales | 20 | 0
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |
Sales by segment of business |  |
Sales | 14 | 0
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales | $ 1,517 | 1,475
Percent Change (as a percent) | 2.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales | $ 1,103 | 1,095
Percent Change (as a percent) | 0.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales | $ 414 | 380
Percent Change (as a percent) | 8.90% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |
Sales by segment of business |  |
Sales | $ 415 | 431
Percent Change (as a percent) | (3.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |
Sales by segment of business |  |
Sales | $ 132 | 166
Percent Change (as a percent) | (20.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |
Sales by segment of business |  |
Sales | $ 283 | 265
Percent Change (as a percent) | 6.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |
Sales by segment of business |  |
Sales | $ 578 | 513
Percent Change (as a percent) | 12.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |
Sales by segment of business |  |
Sales | $ 578 | 513
Percent Change (as a percent) | 12.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |
Sales by segment of business |  |
Sales | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |
Sales by segment of business |  |
Sales | $ 248 | 284
Percent Change (as a percent) | (12.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |
Sales by segment of business |  |
Sales | $ 204 | 247
Percent Change (as a percent) | (17.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |
Sales by segment of business |  |
Sales | $ 44 | 37
Percent Change (as a percent) | 18.90% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |
Sales by segment of business |  |
Sales | $ 276 | 247
Percent Change (as a percent) | 11.70% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |
Sales by segment of business |  |
Sales | $ 189 | 169
Percent Change (as a percent) | 11.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |
Sales by segment of business |  |
Sales | $ 87 | 78
Percent Change (as a percent) | 11.50% |
MEDICAL DEVICES |  |
Sales by segment of business |  |
Sales | $ 6,767 | 6,293
Percent Change (as a percent) | 7.50% |
MEDICAL DEVICES | U.S. |  |
Sales by segment of business |  |
Sales | $ 3,161 | 3,092
Percent Change (as a percent) | 2.20% |
MEDICAL DEVICES | International |  |
Sales by segment of business |  |
Sales | $ 3,606 | 3,201
Percent Change (as a percent) | 12.70% |
MEDICAL DEVICES | Diabetes Care |  |
Sales by segment of business |  |
Sales | $ 339 | 399
Percent Change (as a percent) | (15.00%) |
MEDICAL DEVICES | Diabetes Care | U.S. |  |
Sales by segment of business |  |
Sales | $ 117 | 154
Percent Change (as a percent) | (24.00%) |
MEDICAL DEVICES | Diabetes Care | International |  |
Sales by segment of business |  |
Sales | $ 222 | 245
Percent Change (as a percent) | (9.40%) |
MEDICAL DEVICES | Diagnostics |  |
Sales by segment of business |  |
Sales | $ 0 | 1
MEDICAL DEVICES | Diagnostics | U.S. |  |
Sales by segment of business |  |
Sales | 0 | 0
MEDICAL DEVICES | Diagnostics | International |  |
Sales by segment of business |  |
Sales | 0 | 1
MEDICAL DEVICES | Interventional Solutions |  |
Sales by segment of business |  |
Sales | $ 640 | 549
Percent Change (as a percent) | 16.60% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |
Sales by segment of business |  |
Sales | $ 304 | 279
Percent Change (as a percent) | 9.00% |
MEDICAL DEVICES | Interventional Solutions | International |  |
Sales by segment of business |  |
Sales | $ 336 | 270
Percent Change (as a percent) | 24.40% |
MEDICAL DEVICES | Orthopaedics |  |
Sales by segment of business |  |
Sales | $ 2,250 | 2,275
Percent Change (as a percent) | (1.10%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales | $ 1,307 | 1,359
Percent Change (as a percent) | (3.80%) |
MEDICAL DEVICES | Orthopaedics | International |  |
Sales by segment of business |  |
Sales | $ 943 | 916
Percent Change (as a percent) | 2.90% |
MEDICAL DEVICES | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales | $ 363 | 352
Percent Change (as a percent) | 3.10% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales | $ 209 | 209
Percent Change (as a percent) | 0.00% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales | $ 154 | 143
Percent Change (as a percent) | 7.70% |
MEDICAL DEVICES | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales | $ 387 | 398
Percent Change (as a percent) | (2.80%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales | $ 228 | 246
Percent Change (as a percent) | (7.30%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales | $ 159 | 152
Percent Change (as a percent) | 4.60% |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales | $ 696 | 642
Percent Change (as a percent) | 8.40% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales | $ 407 | 391
Percent Change (as a percent) | 4.10% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales | $ 289 | 251
Percent Change (as a percent) | 15.10% |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |
Sales by segment of business |  |
Sales | $ 804 | 883
Percent Change (as a percent) | (8.90%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |
Sales by segment of business |  |
Sales | $ 463 | 513
Percent Change (as a percent) | (9.70%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |
Sales by segment of business |  |
Sales | $ 341 | 370
Percent Change (as a percent) | (7.80%) |
MEDICAL DEVICES | Surgery |  |
Sales by segment of business |  |
Sales | $ 2,423 | 2,271
Percent Change (as a percent) | 6.70% |
MEDICAL DEVICES | Surgery | U.S. |  |
Sales by segment of business |  |
Sales | $ 993 | 995
Percent Change (as a percent) | (0.20%) |
MEDICAL DEVICES | Surgery | International |  |
Sales by segment of business |  |
Sales | $ 1,430 | 1,276
Percent Change (as a percent) | 12.10% |
MEDICAL DEVICES | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales | $ 966 | 877
Percent Change (as a percent) | 10.10% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales | $ 393 | 392
Percent Change (as a percent) | 0.30% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales | $ 573 | 485
Percent Change (as a percent) | 18.10% |
MEDICAL DEVICES | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales | $ 1,127 | 1,074
Percent Change (as a percent) | 4.90% |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales | $ 423 | 423
Percent Change (as a percent) | 0.00% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales | $ 704 | 651
Percent Change (as a percent) | 8.10% |
MEDICAL DEVICES | Surgery | SPECIALTY |  |
Sales by segment of business |  |
Sales | $ 330 | 320
Percent Change (as a percent) | 3.10% |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |
Sales by segment of business |  |
Sales | $ 177 | 180
Percent Change (as a percent) | (1.70%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |
Sales by segment of business |  |
Sales | $ 153 | 140
Percent Change (as a percent) | 9.30% |
MEDICAL DEVICES | Vision Care |  |
Sales by segment of business |  |
Sales | $ 1,115 | 798
Percent Change (as a percent) | 39.70% |
MEDICAL DEVICES | Vision Care | U.S. |  |
Sales by segment of business |  |
Sales | $ 440 | 305
Percent Change (as a percent) | 44.30% |
MEDICAL DEVICES | Vision Care | International |  |
Sales by segment of business |  |
Sales | $ 675 | 493
Percent Change (as a percent) | 36.90% |
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales | $ 807 | 683
Percent Change (as a percent) | 18.20% |
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales | $ 309 | 256
Percent Change (as a percent) | 20.70% |
MEDICAL DEVICES | Vision Care | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales | $ 498 | 427
Percent Change (as a percent) | 16.60% |
MEDICAL DEVICES | Vision Care | SURGICAL |  |
Sales by segment of business |  |
Sales | $ 308 | 115
MEDICAL DEVICES | Vision Care | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales | 131 | 49
MEDICAL DEVICES | Vision Care | SURGICAL | International |  |
Sales by segment of business |  |
Sales | $ 177 | $ 66

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |